Table 1.
Population characteristics
| n | Average (SD) | Minimum | Maximum | |||
|---|---|---|---|---|---|---|
| Age | 160 | 35.84 (12.64) | 18 | 61 | ||
| Gender | 160 | Female: 100 (62.5%) Male: 60 (37.5%) | ||||
| MADRS week 0 | 160 | 29.82 (5.53) | 21 | 47 | ||
| Intensity side effects week 2 | Abdominal pain | 159 | 11.89 (2.66) | 1 | 15 | |
| Agitation | 160 | 3.02 (4.41) | 1 | 25 | ||
| Anorgasmia | 156 | 2.09 (3.47) | 1 | 25 | ||
| Blurred vision | 160 | 1.45 (1.75) | 1 | 15 | ||
| Constipation | 159 | 1.74 (2.45) | 1 | 16 | ||
| Decreased appetite | 159 | 3.03 (5.21) | 1 | 25 | ||
| Decreased libido | 159 | 2.65 (4.59) | 1 | 25 | ||
| Decreased sleep | 159 | 3.2 (5.21) | 1 | 25 | ||
| Diarrhea | 159 | 2.09 (2.95) | 1 | 16 | ||
| Drowsiness/ somnolence | 159 | 4.59 (5.95) | 1 | 25 | ||
| Dry mouth | 160 | 2.50 (3.48) | 1 | 25 | ||
| Dyspepsia | 159 | 2.50 (3.58) | 1 | 25 | ||
| Dizziness | 160 | 2.09 (2.95) | 1 | 20 | ||
| Edema | 160 | 1.28 (2.24) | 1 | 25 | ||
| Flushing | 160 | 1.48 (1.78) | 1 | 15 | ||
| Headache | 159 | 2.79 (3.22) | 1 | 20 | ||
| Increased appetite | 160 | 1.93 (3.12) | 1 | 20 | ||
| Increased libido | 158 | 1.22 (.98) | 1 | 9 | ||
| Increased sleep | 160 | 2.97 (4.82) | 1 | 25 | ||
| Nausea | 159 | 3.40 (3.94) | 1 | 20 | ||
| Nervousness | 160 | 3.13 (4.65) | 1 | 20 | ||
| Other | 144 | 1.85 (2.92) | 1 | 20 | ||
| Postural hypotension | 160 | 1.53 (1.80) | 1 | 15 | ||
| Sweating | 159 | 2.33 (3.50) | 1 | 20 | ||
| Tremor | 160 | 1.62 (1.92) | 1 | 15 | ||
| Myoclonus | 160 | 1.36 (1.58) | 1 | 12 | ||
| Weight gain | 158 | 1.30 (1.36) | 1 | 16 | ||
| Weight loss | 160 | 1.21 (1) | 1 | 9 | ||
| Weakness/fatigue | 160 | 3.73 (5.26) | 1 | 25 |
Abbreviations: MADRS, Montgomery-Asberg Depression Rating Scale.